All News

Please join #ACR20 for late breaking abstract on Ziritaxestat, selective autotaxin inhibitor. Phase 2a trial with stats significant effect on skin score and well tolerated. @UMIntMed Session Date Monday, November 9 Presentation Time: 12:15 PM - 12:30 PM ET

Dr. Dinesh Khanna sclerodermaUM ( View Tweet)

Nov 06, 2020

ILD in SSc has grave consequences. Abstr#393 Claims database in Ontario shows relevant Scleroderma ILD occurred in 17% of >3000 pts with nearly double the mortality #ACR20 @RheumNow @CRASCRRheum #bestinclass https://t.co/K3UXvuxBcp

Janet Pope Janetbirdope ( View Tweet)

Nov 06, 2020

Dr. Dinesh Khanna (@sclerodermaUM): In post-hoc analysis of focuSSed trial of tocilizumab vs. placebo, disease duration, male gender, elevated acute phase reactants, and anti-SCL-70 Ab have a larger beneficial effect on FVC in early SSc-ILD. #ATS2020 #MiniSymposia @UMIntMed 10/

ATS Clinical Problems Assembly ATSCPAssembly ( View Tweet)

Nov 05, 2020

RheumNow Podcast – ACR 20 is Coming to Town (10.30.20)

Save

d Jack Cush, MD

Oct 29, 2020

Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on RheumNow.com

Read Article

Abatacept in Early Systemic Sclerosis (ASSET study)

Save

d Jack Cush, MD

Oct 29, 2020

An open-label extension of the ASSET trial (abatacept in diffuse cutaneous systemic sclerosis) showed continued safety with significant improvements in the modified Rodnan Skin Score (mRSS) at 12 months, suggesting abatacept (ABA) may benefit early systemic sclerosis (SSc).

Read Article

FDA Invites Patient Input on Systemic Sclerosis Drug Development

Save

d Jack Cush, MD

Oct 28, 2020

While there have been several promising new agents for systemic sclerosis, many have failed - with all noting the difficulties in appropriate outcomes and endpoints for clinical trials. With this in mind, the FDA was interested in hearing patients’ perspectives on systemic sclerosis and new drug development, and held a virtual meeting on 10/13/20.

Read Article

NEW RESEARCH: Abatacept in the treatment of diffuse cutaneous #SystemicSclerosis; clinically meaningful improvements in mRSS and other outcome measures were observed when patients transitioned to open-label #abatacept treatment https://t.co/tDSo3u8hAY #LancetRheumatology https://t.co/Nc8XYc1URW

Links:

DEFINE_ME

The Lancet Rheumatology TheLancetRheum ( View Tweet)

Oct 21, 2020

RheumNow Podcast – Good Time Charlie…. (10.16.20)

Save

d Jack Cush, MD

Oct 15, 2020

Dr. Jack Cush sings the news and journal reports from the past week on RheumNow.com.

Read Article

1) If you are have diffuse scleroderma and have previously participated in a clinical trial, we need your help! You will be asked to watch video tutorial and answer a survey which will take you 20 minutes to complete. the study is supported by @WeAreSRUK @scleroderma @srfcure

Dr. Dinesh Khanna sclerodermaUM ( View Tweet)

Oct 06, 2020

Slow Lung Decline Typical in Systemic Sclerosis

Save

d RheumNow

Sep 30, 2020

The interstitial lung disease that develops in a subset of patients with systemic sclerosis tends to be heterogeneous, with the majority of patients experiencing a slow pattern of decline in lung function, analysis of outcomes in the European Scleroderma Trials and Research (EUSTAR) database foun

Read Article

Novel Biologic Promising in Mid-Stage Scleroderma Trial

Save

d RheumNow

Sep 29, 2020

The anti-interleukin agent romilkimab showed significant benefits on skin fibrosis among patients with systemic sclerosis in a phase II trial, researchers reported.

Read Article

RheumNow Podcast – Cardiovascular Risk in Psoriatic Disease (9.25.20)

Save

d Jack Cush, MD

Sep 24, 2020

Dr. Jack Cush reviews the news and Journal articles from the past week on RheumNow.com.

Read Article

Romilkimab Effective in Early Diffuse Systemic Sclerosis

Save

d Jack Cush, MD

Sep 24, 2020

A phase II study of patients with early diffuse systemic sclerosis (SSc) has demonstrated improvement in SSc skin outcomes by targeting T cells and fibrosis with the bispecific monoclonal antibody romilkimab (RMK).

Read Article

Is Mortality Improving in Systemic Sclerosis?

Save

d Jack Cush, MD

Aug 16, 2020

Systemic sclerosis (SSc) is a progressive autoimmune disorder that causes premature death, usually from lung, GI, or renal disease. While treatment efforts have been frustrating advances in care may have altered the risk of death according to population data showing that while SSc mortality increased from 1968 through 2000, it has declined since 2001.

Read Article

The RheumNow Podcast is up - Top 13 Rheumatology Centers in the US; anakinra & colchicine in COVID, unload the loading dose, CB2 in Scleroderma. Watch it here>> https://t.co/5LIIi7Pwg1 or listen to the podcast here>> https://t.co/5LIIi7Pwg1

Links:

https://bit.ly/2PeGfVs

Dr. John Cush RheumNow ( View Tweet)

Aug 02, 2020

RheumNow Podcast - Top 13 Rheumatology Centers (7-31-20)

Save

d Jack Cush, MD

Jul 31, 2020

Dr. Jack Cush reviews the news and TOP 13 list of Best Rheumatology Hospitals.

Read Article

Spanish registry of 3679 SLE pts finds 13.6% had polyautoimmunity (SLE plus another autoimmune Dz), Dx as thyroiditis (8%), Sjogrens (14%) secondary APS (14%). Incr odds in female, w/ ILD, Raynauds, SSA/SSB/RNP but LESS w/ antimalarial drugs [0.50] https://t.co/duTqepvmLR

Links: